TY  - JOUR
AU  - Valdés Delgado, Teresa
AU  - Guerra Veloz, María Fernanda
AU  - Castro Laria, Luisa
AU  - Maldonado Pérez, Belén
AU  - Perea Amarillo, Raúl
AU  - Merino Bohórquez, Vicente
AU  - Sáez, Antonia
AU  - Caunedo Álvarez, Ángel
AU  - Argüelles Arias, Federico
PY  - 2020
DO  - 10.17235/reed.2020.6539/2019
SN  - 1130-0108
UR  - http://hdl.handle.net/10668/16287
T2  - Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva
AB  - between 30 % and 40 % of patients treated with infliximab lose response during maintenance. Therapeutic drug monitoring could be used to optimize management in these situations. However, infliximab serum levels are not well defined. The aim of this...
LA  - en
KW  - Adult
KW  - Antibodies, Monoclonal
KW  - Crohn Disease
KW  - Female
KW  - Gastrointestinal Agents
KW  - Humans
KW  - Infliximab
KW  - Male
KW  - Middle Aged
KW  - Remission Induction
KW  - Retrospective Studies
KW  - Treatment Outcome
TI  - Cut-off ranges of infliximab serum levels in Crohn's disease in the clinical practice.
TY  - research article
VL  - 112
ER  -